JP2019520034A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520034A5
JP2019520034A5 JP2018550322A JP2018550322A JP2019520034A5 JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5 JP 2018550322 A JP2018550322 A JP 2018550322A JP 2018550322 A JP2018550322 A JP 2018550322A JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018550322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520034A (ja
JP7491666B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/059071 external-priority patent/WO2017178653A2/en
Publication of JP2019520034A publication Critical patent/JP2019520034A/ja
Publication of JP2019520034A5 publication Critical patent/JP2019520034A5/ja
Priority to JP2022112873A priority Critical patent/JP7549626B2/ja
Application granted granted Critical
Publication of JP7491666B2 publication Critical patent/JP7491666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018550322A 2016-04-14 2017-04-14 新規な抗SIRPa抗体およびそれらの治療適用 Active JP7491666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022112873A JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
US62/322,707 2016-04-14
EP17305182 2017-02-17
EP17305182.2 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022112873A Division JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Publications (3)

Publication Number Publication Date
JP2019520034A JP2019520034A (ja) 2019-07-18
JP2019520034A5 true JP2019520034A5 (https=) 2020-05-21
JP7491666B2 JP7491666B2 (ja) 2024-05-28

Family

ID=65529144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018550322A Active JP7491666B2 (ja) 2016-04-14 2017-04-14 新規な抗SIRPa抗体およびそれらの治療適用
JP2022112873A Active JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022112873A Active JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Country Status (24)

Country Link
US (3) US11279766B2 (https=)
EP (1) EP4438626A3 (https=)
JP (2) JP7491666B2 (https=)
KR (1) KR102355240B1 (https=)
CN (1) CN115785272A (https=)
CL (1) CL2018002898A1 (https=)
DK (1) DK3443010T3 (https=)
ES (1) ES2990971T3 (https=)
FI (1) FI3443010T3 (https=)
HR (1) HRP20241316T1 (https=)
HU (1) HUE068840T2 (https=)
IL (1) IL262251B2 (https=)
LT (1) LT3443010T (https=)
MA (1) MA44665B1 (https=)
MD (1) MD3443010T2 (https=)
MX (1) MX2018012434A (https=)
PH (1) PH12018550160B1 (https=)
PL (1) PL3443010T3 (https=)
RS (1) RS66062B1 (https=)
SA (1) SA518400237B1 (https=)
SI (1) SI3443010T1 (https=)
SM (1) SMT202400438T1 (https=)
UA (1) UA126658C2 (https=)
ZA (1) ZA201806293B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL262251B2 (en) * 2016-04-14 2023-09-01 Ose Immunotherapeutics New anti-syrap antibodies and their medical applications
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
BR112020001653A2 (pt) * 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
EP3694881A1 (en) * 2017-10-13 2020-08-19 OSE Immunotherapeutics Modified anti-sirpa antibodies and uses thereof
JP2021517130A (ja) 2018-03-13 2021-07-15 オーセ イミュノセラピューティクスOse Immunotherapeutics 抗ヒトSIRPav1抗体の使用および抗v1抗体を製造する方法
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン, インコーポレイテッド 抗cd47及び抗cd20による血液癌の治療
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
KR102896511B1 (ko) * 2022-09-07 2025-12-08 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
US20100215640A1 (en) * 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Cd47部分ペプチドと抗shps−1モノクロナール抗体
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
EP2573112A1 (en) 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
HRP20150553T1 (hr) 2009-05-15 2015-08-28 University Health Network Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
WO2012149416A2 (en) 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
BR112013031762A2 (pt) * 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
NZ710695A (en) 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN106456749B (zh) 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
WO2017068164A1 (en) 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
BR112018070823A2 (pt) 2016-04-14 2019-02-05 Ose Immunotherapeutics anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
IL262251B2 (en) * 2016-04-14 2023-09-01 Ose Immunotherapeutics New anti-syrap antibodies and their medical applications
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
KR102702926B1 (ko) * 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
CN118271443A (zh) 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
EP3694881A1 (en) 2017-10-13 2020-08-19 OSE Immunotherapeutics Modified anti-sirpa antibodies and uses thereof
JP2021517130A (ja) 2018-03-13 2021-07-15 オーセ イミュノセラピューティクスOse Immunotherapeutics 抗ヒトSIRPav1抗体の使用および抗v1抗体を製造する方法
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗sirpa抗体およびその使用法
SG11202012338QA (en) 2018-07-10 2021-01-28 Univ Kobe Nat Univ Corp ANTI-SIRPa ANTIBODY
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
JP2022507295A (ja) 2018-11-14 2022-01-18 アーチ オンコロジー,インコーポレイテッド 治療用SIRPα抗体
JP7451520B2 (ja) 2018-11-15 2024-03-18 ビョンディス・ビー.ブイ. ヒト化抗SIRPα抗体
WO2020180811A1 (en) 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
AU2020286285A1 (en) 2019-08-20 2021-03-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-SIRPa antibodies
CN111635458B (zh) 2020-03-20 2026-02-17 健信生物科技(宁波)有限公司 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN111995682B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 抗人SIRPα单克隆抗体及其用途
CN112010979B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 一种抗人SIRPα单克隆抗体及其用途
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途

Similar Documents

Publication Publication Date Title
JP2019520034A5 (https=)
JP2022169504A5 (https=)
TWI701259B (zh) 4﹘1bb抗體及其製備方法和應用
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
US9273136B2 (en) Fully human anti-human NKG2D monoclonal antibodies
CN113543804A (zh) 抗lilrb2抗体及其使用方法
BR112021010394A2 (pt) Anticorpo anti-4-1bb e uso do mesmo
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN116239698A (zh) 双功能融合蛋白及其医药用途
JP2020504095A (ja) 抗PD−L1抗体との組み合わせのための抗Tim−3抗体
JP2020504171A (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
JP2018531914A (ja) CD155/TIGIT経路およびTGF−βのアンタゴニストを介してがんを処置するための組成物および方法
JP2021500916A5 (https=)
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
CN116693686A (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
KR20200079561A (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN107266571A (zh) 抗‑mcam抗体及相关使用方法
SG187945A1 (en) Anti-ox40 antibodies and methods of using the same
KR20100014588A (ko) 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN115785272A (zh) 新型抗-SIRPa抗体及其治疗应用
US20210379194A1 (en) Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
US20150125397A1 (en) Dual specific binding proteins directed against immune cell receptors and autoantigens
CA3121420A1 (en) Anti-il-27 antibodies and uses thereof
WO2022143552A1 (zh) Pd-1结合分子及其应用